Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes patients: The association between remaining β-cell function and the achievement of the glycated hemoglobin target 1 year after initiation.

Usui R, Sakuramachi Y, Seino Y, Murotani K, Kuwata H, Tatsuoka H, Hamamoto Y, Kurose T, Seino Y, Yabe D

Journal of diabetes investigation13 Dec 2017Cited by 29 (Europe PMC)

PMID29106046PMCIDPMC6031501DOI10.1111/jdi.12773PepBankPUB-29106046

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In Japanese adults with type 2 diabetes switched to a liraglutide and basal insulin combination, 57 of 72 continued the therapy for 54 weeks.
In plain wordsIn Japanese adults with type 2 diabetes switched to liraglutide plus basal insulin, 57 of 72 stayed on it for 54 weeks.
Peptide
Liraglutide
Outcome
Not applicableContinuation of liraglutide and basal insulin for 54 weeks
Study
n = 72
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Among the 72 participants who received a prescription change from multiple-dose insulin and basal insulin-supported oral therapy to liraglutide and basal insulin combination, 57 continued the therapy for 54 weeks.
1 context sentence(design, population, supporting numbers)
Summary · context
Type 2 diabetes patients who received a prescription change from insulin therapy, both multiple-dose insulin and basal insulin-supported oral therapy, to liraglutide and basal insulin combination and continued the therapy for 54 weeks without additional oral antidiabetic drugs or bolus insulin were…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2910604601
02HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In Japanese adults with type 2 diabetes who continued liraglutide and basal insulin without other additions, seven participants reached HbA1c below 7.0% at 54 weeks and 30 did not.
In plain wordsIn Japanese adults with type 2 diabetes on liraglutide plus basal insulin, seven people reached the HbA1c target and 30 did not.
Peptide
Liraglutide
Outcome
Not applicableAchievement of HbA1c below 7.0% at 54 weeks
Study
n = 37
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Of those who continued the therapy without receiving additional oral antidiabetic drugs or bolus insulin, seven participants achieved glycated hemoglobin < 7.0% at 54 weeks, but 30 participants did not.
1 context sentence(design, population, supporting numbers)
Summary · context
Type 2 diabetes patients who received a prescription change from insulin therapy, both multiple-dose insulin and basal insulin-supported oral therapy, to liraglutide and basal insulin combination and continued the therapy for 54 weeks without additional oral antidiabetic drugs or bolus insulin were…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2910604602
03HumanNot a test of Liraglutide aloneObservational studyMechanism
In Japanese adults with type 2 diabetes on liraglutide and basal insulin, participants who reached HbA1c below 7.0% had a significantly higher C-peptide immunoreactivity index.
In plain wordsIn Japanese adults with type 2 diabetes on liraglutide plus basal insulin, those who reached the HbA1c target had higher remaining beta-cell function.
Peptide
Liraglutide
Outcome
IncreaseC-peptide immunoreactivity index in achievers versus non-achievers
Study
n = 37
Comparator
Participants who did not reach HbA1c below 7.0%
Outcome group
Glycemic control · Endocrine and hormones
Source sentences
Summary
The participants who achieved glycated hemoglobin < 7.0% at 54 weeks had a significantly higher C-peptide immunoreactivity index, a β-cell function-related index frequently used in Japanese clinical settings.
1 context sentence(design, population, supporting numbers)
Summary · context
Type 2 diabetes patients who received a prescription change from insulin therapy, both multiple-dose insulin and basal insulin-supported oral therapy, to liraglutide and basal insulin combination and continued the therapy for 54 weeks without additional oral antidiabetic drugs or bolus insulin were…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2910604603
04HumanNot a test of Liraglutide aloneObservational studyMechanism
In Japanese adults with type 2 diabetes on liraglutide and basal insulin, receiver operating curve analysis gave a C-peptide immunoreactivity index cut-off of 1.103 for reaching HbA1c below 7.0%.
In plain wordsIn Japanese adults with type 2 diabetes on liraglutide plus basal insulin, a beta-cell index cut-off of 1.103 separated those who reached the HbA1c target.
Peptide
Liraglutide
Outcome
Not applicableC-peptide index cut-off for achieving HbA1c below 7.0%
Study
n = 37
Outcome group
Glycemic control · Endocrine and hormones
Measurements
C-peptide immunoreactivity index cut-off
1.103 index
HbA1c <7.0% at 54 weeks
Source sentences
Summary
The receiver operating curve analysis showed that the C-peptide immunoreactivity index cut-off value for the achievement of glycated hemoglobin <7.0% at 54 weeks is 1.103.
1 context sentence(design, population, supporting numbers)
Summary · context
Type 2 diabetes patients who received a prescription change from insulin therapy, both multiple-dose insulin and basal insulin-supported oral therapy, to liraglutide and basal insulin combination and continued the therapy for 54 weeks without additional oral antidiabetic drugs or bolus insulin were…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2910604604

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.